Menu
Search
Home > Courses > HIV Drug Resistance Testing in the Golden Age of Antiretroviral Therapy

HIV Drug Resistance Testing in the Golden Age of Antiretroviral Therapy

HIV Drug Resistance Testing in the Golden Age of Antiretroviral Therapy
Sorry, this learning module is not available for mobile devices.
This video is available at the Physicians Research Network website.

Original Release Date: 6/14/2011
Review Date: 6/14/2011
Presenter
  • Athe Tsibiris, MD, MS
    Assistant Professor of Medicine
    Harvard Medical School
Learning Objectives / Desired Outcomes
At the completion of this educational activity, participants will:
  1. Identify rates of transmitted HIV drug resistance worldwide
  2. Determine the optimal timing of HIV drug resistance testing
  3. Discuss the changing mutation patterns of HIV drug resistance
  4. Understand the relationship between HIV drug resistance and class-sparing regimens.
Presenter Bio
Athe Tsibiris, MD, MS
Athe Tsibris, MD, is an Assistant Professor of Medicine at Harvard Medical School, and Assistant in Medicine at the Massachusetts General Hospital. Dr. Tsibris’s research currently focuses on the characterization of HIV-1 resistance to CCR5 antagonists, and the use of ultra-deep sequencing to demonstrate dynamic HIV-1 escape from CCR5 inhibition in vivo. In addition to his translational, bench-side research, Dr. Tsibris is committed to integrating novel lab findings of HIV drug resistance to improve patient care worldwide, while continuing to be involved in clinical care and teaching.
PRN Learning Modules